CRISPR Therapeutics AG (CRSP): Price and Financial Metrics

CRISPR Therapeutics AG (CRSP)

Today's Latest Price: $93.83 USD

0.74 (-0.78%)

Updated Aug 5 12:20pm

Add CRSP to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 343 in Biotech

See all "A" rated Strong Buy stocks

CRSP Stock Summary

  • CRSP's current price/earnings ratio is 338.96, which is higher than 98% of US stocks with positive earnings.
  • The price/operating cash flow metric for CRISPR Therapeutics AG is higher than 97.36% of stocks in our set with a positive cash flow.
  • As for revenue growth, note that CRSP's revenue has grown 21,738.75% over the past 12 months; that beats the revenue growth of 99.95% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CRISPR Therapeutics AG are SLGL, ZLAB, CLSD, MDWD, and LIFE.
  • Visit CRSP's SEC page to see the company's official filings. To visit the company's web site, go to
CRSP Daily Price Range
CRSP 52-Week Price Range

CRSP Stock Price Chart Technical Analysis Charts

CRSP Price/Volume Stats

Current price $93.83 52-week high $97.82
Prev. close $94.57 52-week low $32.30
Day low $92.00 Volume 454,983
Day high $94.58 Avg. volume 1,041,224
50-day MA $78.37 Dividend yield N/A
200-day MA $60.46 Market Cap 6.58B

CRISPR Therapeutics AG (CRSP) Company Bio

CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company is based in Basel, Switzerland.

CRSP Latest News Stream

Event/Time News Detail
Loading, please wait...

CRSP Latest Social Stream

Loading social stream, please wait...

View Full CRSP Social Stream

Latest CRSP News From Around the Web

Below are the latest news stories about CRISPR Therapeutics AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in August: William Blair Biotech Focus Conference Date: Thursday, August 6, 2020 Panel: 1:00 p.m. ETCanaccord Genuity 40th Annual Growth Conference Date: Thursday, August 13, 2020 Fireside chat: 2:30 p.m. ETA live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at A replay of the webcast will be archived on ...

Yahoo | July 30, 2020

Industry Analysts Just Made A Meaningful Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Revenue Forecasts

CRISPR Therapeutics AG (NASDAQ:CRSP) shareholders will have a reason to smile today, with the analysts making...

Yahoo | July 29, 2020

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -41.30% and -99.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 27, 2020

Crisper Therapeutics shares decline on wider-than-expected loss

Crisper Therapeutics AG shares declined in the extended session Monday after the gene-editing company reported a wider-than-expected loss. Crisper shares declined 2.3% after hours, following a 2% rise in the regular session to close at $92.12. The company reported a second-quarter loss of $79.7 million, or $1.30 a share, compared with a loss of $53.7 million, or $1.01 a share, in the year-ago period. Revenue declined to $44 million from $318 million in the year-ago quarter. Analysts surveyed by FactSet had forecast a loss of 95 cents a share on revenue of $18.1 million.

Yahoo | July 27, 2020

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results

-Dosing re-initiated in clinical trials of CTX001™ for patients with severe hemoglobinopathies- - CTX001 has received orphan drug designation from the U.S. FDA for sickle cell disease (SCD)--Expands regenerative medicine portfolio through a collaboration with University Health Network (UHN), gaining access to hepatocytes-ZUG, Switzerland and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2020.“We continue to make substantial progress driving our multiple, ongoing clinical development programs. Enrollment in our immuno-oncology trials is ongoing, and we’ve re-initiated dos...

Yahoo | July 27, 2020

Read More 'CRSP' Stories Here

CRSP Price Returns

1-mo 11.56%
3-mo 75.42%
6-mo 79.34%
1-year 97.54%
3-year 409.95%
5-year N/A
YTD 54.06%
2019 113.18%
2018 21.68%
2017 15.89%
2016 N/A
2015 N/A

Continue Researching CRSP

Here are a few links from around the web to help you further your research on CRISPR Therapeutics AG's stock as an investment opportunity:

CRISPR Therapeutics AG (CRSP) Stock Price | Nasdaq
CRISPR Therapeutics AG (CRSP) Stock Quote, History and News - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8642 seconds.